Global Blood Therapeutics has seen its sickle cell disease drug approved by the FDA, promising to be the first treatment targeting the root cause of the condition.

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion. As we ...

His previous roles include Chief Research and Development Officer at Reata Pharmaceuticals (NASDAQ:RETA), as well as executive positions at Global Blood Therapeutics (NASDAQ:GBT), Portola ...

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or ...

The Global Blood Micro-Sampling Medical Devices Market is projected to reach USD 2,056.3 million in 2024 which is further anticipated to reach USD 3,272.6 million by 2033 at a CAGR of 5.3%.

Global Thalassemia Market Global Thalassemia Market Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Thalassemia Market by ...

including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide ...

This groundbreaking therapy—benchmarked to global standards ... increasing incidence of blood cancer cases, Qartemi—a pioneering CAR-T cell therapy from Immuneel Therapeutics—stands ...

Earlier, Dr. Patni was Chief Medical Officer at Global Blood Therapeutics, Portola Pharmaceuticals, and Adamas Pharmaceuticals, until their acquisitions by larger companies. He also held roles of ...